Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia

Journal Article · Fri Feb 15 04:00:00 EST 2008 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/j.bbrc.2007.12.029· OSTI ID:21043624

Gupta, Manu; Milani, Lili ^[1]; Hermansson, Monica ^[2]; Simonsson, Bengt ^[3]; Markevaern, Berit ^[4]; Syvaenen, Ann Christine ^[1]; Barbany, Gisela ^[5]

---

1. Molecular Medicine, Department of Medical Sciences, Uppsala University (Sweden)
2. Department of Genetics and Pathology, Uppsala University Hospital (Sweden)
3. Hematology Section, Department of Medical Sciences, Uppsala University Hospital (Sweden)
4. Department of Medicine, Hematology Section, Umea University Hospital (Sweden)
5. Department of Molecular Medicine and Surgery, Clinical Genetics Unit, Karolinska Institute, 171 76 Stockholm (Sweden)

Using a quantitative single nucleotide polymorphism (SNP) assay we have investigated the changes in the expression of the BCR-ABL1 oncogene relative to the wild-type ABL1 and BCR alleles in cells from chronic myeloid leukemia (CML) patients not responding to therapy. The results show a progressive increase in the BCR-ABL1 oncogene expression at the expense of decreased expression of the ABL1 allele, not involved in the fusion. No relative changes in the expression of the two BCR alleles were found. These results demonstrate that allele-specific changes in gene expression, with selective, progressive silencing of the wild-type ABL1 allele in favor of the oncogenic BCR-ABL1 allele occur in CML patients with therapy-resistant disease.

• OSTI ID: 21043624
• Journal Information: Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 3 Vol. 366; ISSN 0006-291X; ISSN BBRCA9
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
MYELOID LEUKEMIA
NUCLEOTIDES
ONCOGENES
PATIENTS
THERAPY